TY - JOUR
T1 - Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave
T2 - A Brief Report From the TERAVOLT Analysis
AU - TERAVOLT study group
AU - Bestvina, Christine M.
AU - Whisenant, Jennifer G.
AU - Torri, Valter
AU - Cortellini, Alessio
AU - Wakelee, Heather
AU - Peters, Solange
AU - Roca, Elisa
AU - De Toma, Alessandro
AU - Hirsch, Fred R.
AU - Mamdani, Hirva
AU - Halmos, Balazs
AU - Arrieta, Oscar
AU - Metivier, Anne Cecile
AU - Fidler, Mary J.
AU - Rogado, Jacobo
AU - Presley, Carolyn J.
AU - Mascaux, Celine
AU - Genova, Carlo
AU - Blaquier, Juan Bautista
AU - Addeo, Alfredo
AU - Finocchiaro, Giovanna
AU - Khan, Hina
AU - Mazieres, Julien
AU - Morgillo, Floriana
AU - Bar, Jair
AU - Aujayeb, Avinash
AU - Mountzios, Giannis
AU - Scotti, Vieri
AU - Grosso, Federica
AU - Geraedts, Erica
AU - Zhumagaliyeva, Ardak N.
AU - Horn, Leora
AU - Garassino, Marina Chiara
AU - Baena, Javier
N1 - Funding Information:
Disclosure: Dr. Bestvina declares receiving personal consulting fees from AstraZeneca, Bristol-Myers Squibb, CVS, Genentech, Jazz, Johnson & Johnson, Novartis, Pfizer, Regeneron/Sanofi, Seattle Genetics, and Takeda; receiving speaker bureau fees for Merck; and having institutional contracted research from AstraZeneca and Bristol-Myers Squibb. Dr. Whisenant reports receiving support for this research from International Association for the Study of Lung Cancer/Lung Ambition Alliance and personal royalties/licenses from Anasys Instruments. Dr. Cortellini reports receiving speaker fees/grant consultancies from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Eisai, and Novartis. Dr. Wakelee reports receiving research funding to the institution from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, Bristol-Myers Squibb, Clovis Oncology, Genentech/Roche, Merck, Novartis, SeaGen, Xcovery, and Helsinn; compensated advisory board work from AstraZeneca, Janssen, Daiichi Sankyo, Blueprint, and Mirati; and uncompensated advisory board work for Merck and Genentech/Roche. Dr. Peters served as consultant/advisory board member for AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, Foundation Medicine, Illumina, Imedex, IQVIA, Incyte, Janssen, Medscape, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, and Takeda; reports receiving speaker fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp & Dohme, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, and Takeda; and receiving grants/research supports from (sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, GlaxoSmithKline, Illumina, Eli Lilly, Merck Sharp & Dohme, Merck Serono, Mirati, Novartis, Pfizer, Phosplatin Therapeutics, and Roche/Genentech (all to institution). Dr. De Toma reports receiving personal payment from AstraZeneca. Dr. Hirsch reports receiving personal consulting fees from Bristol-Myers Squibb, AstraZeneca/Daiichi, Sanofi/Regeneron, Novartis, Merck, Amgen, and OncoCyte. Dr. Mamdani reports receiving personal consulting fees from Zentalis and personal payments from AstraZeneca. Dr. Halmos reports receiving grants or contracts from AstraZeneca, Merck, Bristol-Myers Squibb, Novartis, Amgen, Mirati, Pfizer, Advaxis, GlaxoSmithKline, TPT, Apollomics, Genentech, Takeda, Daiichi, and Beigene; personal consulting fees from AstraZeneca, Bristol-Myers Squibb, Pfizer, Beigene, Mirati, Janssen, Merck, Takeda, Boehringer Ingelheim, and Veracyte. Dr. Arrieta reports receiving institutional grants and contracts from AstraZeneca, Merck, and Roche; personal payments from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, and Roche. Dr. Metivier reports receiving personal payment for expert testimony from Merck Sharp & Dohme, Novartis, and Takeda. Dr. Fidler reports receiving consulting fees from Silverback, G1 Therapeutics, AstraZeneca, Rakuten, Beigene, and Daiichi; speakers bureau from Beigene and Jazz; and research support from Biodesix, Pfizer/EMD Serono, AstraZeneca, Jounce, CytomX Therapeutics, Merck, Novartis, Rakuten, and Alkermes. Dr. Rogado reports receiving personal fees from Roche, AstraZeneca, Merck, Ferrer, Persan Farma, and Fresenius Kabi; travel expenses from Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, and AstraZeneca; and advisor consultancies from Fresenius Kabi. Dr. Mascaux reports receiving personal consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Kephren, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, Takeda, and Janssen; receiving support for travel from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, and Roche; and having European Patent Application EP19305434.3. Dr. Genova reports receiving personal honoraria for presentations from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Roche, and Takeda. Dr. Addeo reports receiving consulting fees from AstraZeneca, Bristol-Myers Squibb, Pfizer, Janssen, Merck, Takeda, Roche, Amgen, Novartis, and Sanofi. Dr. Khan reports receiving study funding by the Bristol-Myers Squibb Foundation (BMSF) for Diversity in Clinical Trials and having participated to advisory boards for Sanofi Genzyme. Dr. Mazieres reports receiving personal fees from Merck, AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Novartis, Daiichi, and Pfizer; and grants from Roche, AstraZeneca, and Pierre Fabre. Dr. Bar reports receiving institutional research grants from AstraZeneca, Takeda, OncoHost, ImmuneAI, Merck Sharp & Dohme, Roche, Eli Lilly, ICRF, and Tel-Aviv University; receiving personal consulting fees from Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, AstraZeneca, Novartis, Pfizer, Causalis, Bayer, and Takeda; having participation in an advisory board for Roche and AstraZeneca; having a leadership role in the Lung Ambition Alliance—Israel; and having stock/stock options in Causalis. Dr. Mountzios reports receiving grants or contracts from AstraZeneca, Bristol-Myers Squibb, Amgen, Gilead Pharmaceuticals, GlaxoSmithKline, Immunomedics, Merck, Merck Sharp & Dohme, Novartis, Roche, and Sanofi; consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Takeda; and support for meetings/travel from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Roche, Sanofi, and Takeda. Dr. Scotti reports receiving consulting fees from Roche and Boehringer Ingelheim; personal payments from AstraZeneca, Takeda, Bristol-Myers Squibb, Merck Sharp & Dohme, Daiichi Sankyo, Boehringer Ingelheim, Roche, Pfizer, and Novartis; participation in an advisory board from AstraZeneca, Takeda, Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Pfizer, and Novartis. Dr. Grosso reports receiving personal fees for advisory role, speaker engagements, and travel and accommodation expenses from Merck Sharp & Dohme, Novocure, Bristol Myer Squibb, Boehringer Ingelheim, Pharmamar, and Novartis; personal fees and travel support from Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Novocure, and Pharmamar; speakers bureau for Novocure; and honoraria for educational events from Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, and Novartis. Dr. Horn reports employment from AstraZeneca. Dr. Garassino reports receiving grants and research support to the institution from Eli Lilly, Merck Sharp & Dohme, Pfizer (MISP), AstraZeneca, Merck Sharp & Dohme International GmbH, Bristol-Myers Squibb, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, MedImmune, Novartis, Pfizer, Roche, Takeda, Tiziana, Foundation Medicine, GlaxoSmithKline, and Spectrum Pharmaceuticals; personal consulting fees from AstraZeneca, Merck Sharp & Dohme International GmbH, Bristol-Myers Squibb, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, Takeda, Seattle Genetics, 1 Mirati, Daiichi Sankyo, Regeneron, and Merck; speaker fees from AstraZeneca, Merck Sharp & Dohme, and Takeda; and travel and accommodation expenses from Roche. Dr. Espinar reports receiving personal fees from AstraZeneca, Bristol-Myers Squibb, and Roche and nonfinancial support from Angelini. All the declared conflict of interests are outside the submitted work. The remaining authors declare no conflict of interest.
Publisher Copyright:
© 2022 The Authors
PY - 2022/8
Y1 - 2022/8
N2 - Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
AB - Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
KW - COVID-19
KW - Cancer
KW - NSCLC
KW - Registry
KW - TERAVOLT
KW - Thoracic
UR - http://www.scopus.com/inward/record.url?scp=85134290270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134290270&partnerID=8YFLogxK
U2 - 10.1016/j.jtocrr.2022.100335
DO - 10.1016/j.jtocrr.2022.100335
M3 - Article
AN - SCOPUS:85134290270
SN - 2666-3643
VL - 3
JO - JTO Clinical and Research Reports
JF - JTO Clinical and Research Reports
IS - 8
M1 - 100335
ER -
